tbuckley/cabot-search huggingface dataset:
Comparison of Laboratory Assays to Measure Rivaroxaban and Dabigatran
Authors: Severine Robert, François Mullier, Hassan Mekouar, Florence Polet, Jonathan Douxfils, Françoise Biot, Marie-Christine Lambert, Justine Baudar, Philippe Devel, Christian J. Chatelain, Bernard Chatelain, Jean-Michel Dogné
Journal: Blood (2010)
Complete Response to Clofarabine Is Durable and Correlates with Survival in Previously Untreated Older Adult Patients with Acute Myeloid Leukemia (AML) and Unfavorable Prognostic Factors.
Authors: Janice Gabrilove, Stefan Faderl, Harry P Erba, David F. Claxton, M. Arellano, Roger M Lyons, Tibor J. Kovacsovics, Stephen Eckert, Dirk Huebner, Hagop M. Kantarjian
Journal: Blood (2009)
Spinal manipulation, medication, or home exercise with advice for acute and subacute neck pain
Authors: Gert Bronfort, Roni L Evans, Alfred V. Anderson, Kenneth H. Svendsen, Yiscah Bracha, Richard H. Grimm
Journal: Annals of Internal Medicine (2012)

Evidence to guide the choice of therapy for acute and subacute neck pain is lacking. This randomized, controlled trial aimed to determine the short- and long-term relative efficacy of spinal manipu...
Impact of the addition of rituximab in overall survival in first line chemotherapy in follicular lymphoma: a population-based study from the Spanish Lymphoma Oncology Group (GOTEL)
Authors: M. Torrente, P. Sabin, J. Gomez Codina, Ldela Cruz Merino, M. Llanos, J. Guma I. Padro, C. Quero, A. Blasco, F.R. Garcia Arroyo, A. Rueda
Journal: Annals of Oncology (2016)
A PDGFRα-Mediated Switch toward CD9high Adipocyte Progenitors Controls Obesity-Induced Adipose Tissue Fibrosis
Authors: Geneviève Marcelin, Adaliene Ferreira, Yuejun Liu, Michael Atlan, Judith Aron-Wisnewsky, Véronique Pelloux, Yair Botbol, Marc Ambrosini, Magali Fradet, Christine Rouault, Corneliu Hénégar, Jean-Sébastien Hulot, Christine Poitou, Adriana Torcivia, Raphael Nail-Barthelemy, Jean-Christophe Bichet, Emmanuel L. Gautier, Karine Clément
Journal: Cell Metabolism (2017)
Distinct Levels of Radioresistance in Lgr5+ Colonic Epithelial Stem Cells versus Lgr5+ Small Intestinal Stem Cells
Authors: Guoqiang Hua, Chu Wang, Yan Pan, Zhaoshi Zeng, Sang Gyu Lee, Maria Laura Martin, Adriana Haimovitz-Friedman, Zvi Fuks, Philip B. Paty, Richard Kolesnick
Journal: Cancer Research (2017)

Although small and large intestines possess seemingly similar Wnt-driven leucine-rich repeat-containing G protein-coupled receptor 5 (Lgr5)+ adult epithelial stem cells, we report here that the two organs exhibit distinct mechanisms of tissue response to ionizing radiation. Employing Lgr5-lacZ transgenic mice and Lgr5 in situ hybridization, we found colonic epithelial stem cells (CESC) markedly more radioresistant in vivo than small intestinal crypt base columnar stem cells (CBC; D0 = 6.0 ± 0.3 Gy vs. 1.3 ± 0.1, respectively; P < 0.01). Accordingly, CESCs survived 30 Gy exposure, while CBCs were completely depleted after 15 Gy. EdU incorporation studies indicated that after 19 Gy, CBCs exited growth arrest at 12 hours, resuming normal mitotic activity despite 60% of this population displaying residual γH2AX foci, indicative of persistent unrepaired DNA damage. Checkpoint recovery before complete double-strand break (DSB) repair represents the sine qua non of a newly defined potentially lethal pathophysiology termed checkpoint adaptation. In the small intestinal mucosa, checkpoint adaptation resulted in CBCs succumbing to an 8-fold increase in the incidence of highly lethal chromosomal aberrations and mitotic catastrophe by 48 hours postradiation. In contrast, Lgr5+ CESCs displayed delayed checkpoint recovery at 48 hours post-19 Gy, coordinated with complete DSB repair and regeneration of colonic mucosa originating, at least in part, from surviving CESCs. The discovery that small intestinal CBCs succumb to checkpoint adaptation is the first demonstration that this aberrant cell-cycle response may drive mammalian tissue radiosensitivity. Cancer Res; 77(8); 2124-33. ©2017 AACR.
A Phase I Study of Milatuzumab for Prevention of Acute Graft Versus Host Disease Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant in Patients with Hematologic Malignancies
Authors: Bradley M. Haverkos, Katie Cortright, Leslie A. Andritsos, William Blum, Rebecca B. Klisovic, Sumithira Vasu, David M Goldenberg, William A Wegener, Steven M. Devine, Samantha M. Jaglowski
Journal: Blood (2014)
The In Vivo Activity of Neutralizing B Cell-Activating Factor (BAFF) Antibody in the Treatment of Multiple Myeloma (MM).
Authors: Paola Neri, Shaji Kumar, Mariateresa Fulciniti, Sonia Vallet, Shweta Chhetri, Hiroshi Yasui, Yu-Tzu Tai, Dharminder Chauhan, Teru Hideshima, Pierfrancesco Tassone, Salvatore Venuta, Nikhil C. Munshi, Kenneth C. Anderson, Noopur Raje
Journal: Blood (2006)
In Vitro Cardiotoxicity Potential Comparative Assessments of Chronic Myelogenous Leukemia Tyrosine Kinase Inhibitor Therapies: Dasatinib, Imatinib and Nilotinib.
Authors: Wendy J. Freebern, Hengsheng S. Fang, Martin D. Slade, Susan Wells, Jennifer Canale, John Megill, Branka Grubor, Hong Shi, Anthony Fletcher, Louis Lombardo, Paul Levesque, Francis Y. Lee, Vito G. Sasseville
Journal: Blood (2007)
Desirable Properties of Radiopharmaceuticals for Sentinel Node Mapping in Patients With Breast Cancer Given the Paradigm Shift in Patient Management
Authors: Chun K. Kim, Katherine A. Zukotynski
Journal: Clinical Nuclear Medicine (2017)

Over the past 2 decades, lymphoscintigraphy and sentinel node biopsy have become widely accepted and are used by surgeons to stage many solid cancers, especially breast cancer. However, despite growing experience, there are a number of unresolved issues. In addition, the impact of a new radiopharmaceutical remains to be determined. The present article addresses some of these issues (either unresolved, recurrent, or newly emerged), with a focus on the properties of radiopharmaceuticals used for sentinel node mapping in breast cancer.
Infusion of Ex-Vivo Expanded Donor T Cells To Improve Graft-Derived T-Cell Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation.
Authors: Nicolas Montcuquet, Sylvain Perruche, Benjamin Shipman, Aliette Marandin-Decock, Francis Bonnefoy, Philippe Saas, Eric Robinet, Pierre Tiberghien
Journal: Blood (2007)
A Humanized Anti-IGF-1R Monoclonal Antibody (AVE1642) Synergizes with Bortezomib To Induce Apoptosis in CD45neg Myeloma Cells.
Authors: Geraldine Descamps, Soraya Wuilleme-Toumi, Patricia Gomez-Bougie, Corinne Venot, Friedhelm Bladt Bladt, Regis Bataille, Martine Amiot
Journal: Blood (2006)
The SP142 PD-L1 IHC assay for atezolizumab (atezo) reflects pre-existing immune status in NSCLC and correlates with PD-L1 mRNA
Authors: J. Williams, M. Kowanetz, H. Koeppen, Z. Boyd, E.E. Kadel, D. Smith, M. McCleland, W. Zou, P.S. Hegde
Journal: Annals of Oncology (2016)
P06.20 EGFRvIII: a predictive marker for Temozolomide response in O6-methylguanine-DNA methyltransferase negative glioblastoma cells and tumor xenografts
Authors: N. Struve, T. Brend, L. Ott, C. Petersen, K. Rothkamm, S. C. Short, M. Kriegs
Journal: Neuro-Oncology (2016)
PDTB-01. INDUCTION OF DUAL SPECIFIC PHOSPHATASE SUPPRESSES MEDULLOBLASTOMA PROGRESSION
Authors: Josh Neman, Vahan Martirosian
Journal: Neuro-Oncology (2016)

Brain tumors are the most common cause of childhood oncological death, and medulloblastoma (originating in the cerebellum) is the most common malignant pediatric brain tumor. Current medulloblastoma therapy including surgical resection, whole-brain and spinal cord radiation, and aggressive chemotherapy supplemented by bone marrow transplant yields five-year survival rates of 60–70%. DUSPs (dual-specificity phosphatases) are a heterogeneous group of protein phosphatases that can dephosphorylate both phosphotyrosine and phosphoserine/phosphothreonine residues within the one substrate. DUSPs have been implicated as major modulators of critical signaling pathways (MAPK/ERK/p38/RAF) that are dysregulated in various diseases. Because DUSPs are implicated in cancer initiation and development, the observation that they are abnormally regulated in human tumors has been interpreted as evidence that these enzymes can either suppress or promote carcinogenesis. However, definitive evidence of such roles has been lacking –especially in medulloblastomas. We hypothesize that induction of DUSPs will lead to suppression and invasiveness of medulloblastoma. Our results show DNA microarray from patient medulloblastoma tissue have inverse relationship with survivability –with lower expression of DUSPs in aggressive medulloblastomas. When medulloblastomas were knockdown with DUSP, there was a significant increase in Receptor Tyrosine Kinase, integrins, and their second messenger cascade. Furthermore, DUSP knockdown resulted in induction of large and stable tumor spheres with EMT gene expression signature. We next investigated whether a novel perrilyl alcohol-based small molecule Neo214 elevated DUSPs. Neo214 administration significantly increased DUSPs and reversed EMT-profiling, leading to loss of sphere formation. CONCLUSION: DUSPs are a negative regulatory mechanisms in modulating the activity of oncogenic signaling in medulloblastomas. Thus, the expression DUSPSs in medulloblastoma could be a malignant adaptation for growth and metastasis that could potentially be exploited through targeted therapy for patients benefit.
Observational study of FOLFIRINOX (FFX) for unresectable/recurrent pancreatic cancer (PC) in Japanese patients (pts)(JASPAC 06): final results
Authors: N. Mizuno, A. Todaka, K. Mori, N. Boku, M. Ozaka, H. Ueno, S. Kobayashi, K. Uesugi, N. Kobayashi, H. Hayashi, K. Sudo, N. Okano, Y. Horita, K. Kamei, S. Yukisawa, S. Nakamori, Y. Yachi, T. Henmi, M. Kobayashi, A. Fukutomi
Journal: Annals of Oncology (2016)
Racial Disparities in Pediatric Acute Myeloid Leukemia during Induction
Authors: Lena E. Winestone, Kelly Diringer Getz, Tamara P. Miller, Jennifer J. Wilkes, Leah Sack, Yimei Li, Yuan-Shung Huang, Alix E. Seif, Rochelle Bagatell, Brian T. Fisher, Andrew Epstein, Richard Aplenc
Journal: Blood (2015)
Fatigue and quality of life (QoL) during and after adjuvant treatment by trastuzumab (Herceptin®) among breast cancer patients (BC pts): a case-control study
Authors: S. Noal, N. Heutte, D. Allouache, C. Delcambre, A. Faveyrial, C. Levy, C. Segura, J. Geffrelot, C. Rieux, A. Leconte, B. Clarisse
Journal: Annals of Oncology (2016)
Conditional survival probability in patients with resected oesophageal adenocarcinoma receiving neoadjuvant chemotherapy
Authors: D.M. Graham, F.J. Bannon, F. Noble, R. O'Neill, J.K. Blayney, T.J. Underwood, R.D. Kennedy, R.C. Fitzgerald, R.C. Turkington
Journal: Annals of Oncology (2016)
Exploring the preferences for place of death among cancer patients and their family caregivers.
Authors: Marieberta Vidal
Journal: Journal of Clinical Oncology (2015)

40 Background: Understanding the preferred place of death (POD) for advanced cancer patients (Pts) is very important when they are approaching the end of life. Meeting the preferences of Pts is considered an important palliative care (PC) outcome. Prior studies reported that more than 80% of Pts with terminally ill cancer prefer to die at home. In many countries such as the UK, Italy, Greece, South Korea and Japan home deaths have been falling, but in some states of the US and Canada there are indications of a reversal of trends. Dying at home may be more difficult for Pts in severe physical and psychosocial distress, or when there are social or financial difficulties. The purpose of this study was to determine POD preference among PC Pts in the outpatient center (OC) and the palliative care unit (PCU). Methods: A sectional anonymous questionnaire was administered to advanced cancer Pts and caregivers (PCU patients and OC) between August 2012 and September 2014. PCU Pts responded when there was no delirium and the primary caregiver responded when the patient was unable to respond. In the case of outpatients dyads (patient and caregiver) were assessed. Results: Overall 141/216 (65%) preferred home death. PCU patients preferred home death less than outpatients. Patient and caregiver agreement regarding preferred place of death was 86% (p &lt;0.001). The preferred POD was the same as one month ago for 82/99 (83%) PCU Pts and 111/116 (96%) outpatients, with significant difference between groups (p=0.002). Conclusions: Although home is the preferred POD in advanced cancer Pts, a substantial minority prefer hospital death or no difference. Patients admitted to the PCU have a higher preference for hospital death in comparison to the outpatients, likely reflecting more severe distress because they already tried home care. Pts and caregivers agree on POD in most cases. Personalized assessment of POD preference for both patient and caregiver is needed. [Table: see text]
Efficacy and safety of nivolumab monotherapy in patients with metastatic urothelial cancer (mUC) who have received prior treatment: Results from the phase II CheckMate 275 study
Authors: M.D. Galsky, M. Retz, A.O. Siefker-Radtke, A. Baron, A. Necchi, J. Bedke, E.R. Plimack, D. Vaena, M.-O. Grimm, S. Bracarda, J. Arranz Arija, S.K. Pal, C. Ohyama, A. Saci, A. Lambert, S. Krishnan, A. Azrilevich, P. Sharma
Journal: Annals of Oncology (2016)
Nicotinamide Phosphoribosyltransferase Promotes Pulmonary Vascular Remodeling and Is a Therapeutic Target in Pulmonary Arterial Hypertension
Authors: Jiwang Chen, Justin R. Sysol, Sunit Singla, Shuangping Zhao, Aya Yamamura, Daniela Valdez-Jasso, Taimur Abbasi, Krystyna M. Shioura, Sakshi Sahni, Vamsi Reddy, Arvind Sridhar, Hui Gao, Jaime Torres, Sara M. Camp, Haiyang Tang, Shui Qing Ye, Suzy Comhair, Raed Dweik, Paul Hassoun, Jason X.-J. Yuan, Joe G.N. Garcia, Roberto F. Machado
Journal: Circulation (2017)

Pulmonary arterial hypertension is a severe and progressive disease, a hallmark of which is pulmonary vascular remodeling. Nicotinamide phosphoribosyltransferase (NAMPT) is a cytozyme that regulates intracellular nicotinamide adenine dinucleotide levels and cellular redox state, regulates histone deacetylases, promotes cell proliferation, and inhibits apoptosis. We hypothesized that NAMPT promotes pulmonary vascular remodeling and that inhibition of NAMPT could attenuate pulmonary hypertension.Plasma, mRNA, and protein levels of NAMPT were measured in the lungs and isolated pulmonary artery endothelial cells from patients with pulmonary arterial hypertension and in the lungs of rodent models of pulmonary hypertension. Nampt+/- mice were exposed to 10% hypoxia and room air for 4 weeks, and the preventive and therapeutic effects of NAMPT inhibition were tested in the monocrotaline and Sugen hypoxia models of pulmonary hypertension. The effects of NAMPT activity on proliferation, migration, apoptosis, and calcium signaling were tested in human pulmonary artery smooth muscle cells.Plasma and mRNA and protein levels of NAMPT were increased in the lungs and isolated pulmonary artery endothelial cells from patients with pulmonary arterial hypertension, as well as in lungs of rodent models of pulmonary hypertension. Nampt+/- mice were protected from hypoxia-mediated pulmonary hypertension. NAMPT activity promoted human pulmonary artery smooth muscle cell proliferation via a paracrine effect. In addition, recombinant NAMPT stimulated human pulmonary artery smooth muscle cell proliferation via enhancement of store-operated calcium entry by enhancing expression of Orai2 and STIM2. Last, inhibition of NAMPT activity attenuated monocrotaline and Sugen hypoxia-induced pulmonary hypertension in rats.Our data provide evidence that NAMPT plays a role in pulmonary vascular remodeling and that its inhibition could be a potential therapeutic target for pulmonary arterial hypertension.
CBIO-07. LIPID DROPLETS, A NOVEL DIAGNOSTIC BIOMARKER AND METABOLIC TARGET IN GLIOBLASTOMA
Authors: Feng Geng, Xiang Cheng, Xiaoning Wu, Chunming Cheng, Jeffrey Yunhua Guo, Craig Horbinski, Balveen Kaur, Arnab Chakravarti, Deliang Guo
Journal: Neuro-Oncology (2016)

Lipid metabolism reprogramming is a novel characteristic of malignancies. Identifying the vulnerability of lipid alteration in tumor cells provides a new opportunity to treat cancer. Here, we unraveled that glioblastoma (GBM) patients containing high levels of lipid droplets (LDs), special organelles storing cholesterol esters in cells, presented poor survival. We found that LDs largely formed in tumor tissues from GBM patients, but rarely in low grade of gliomas and normal brain tissues, demonstrating that LDs might serve as a novel diagnostic biomarker and prognostic marker for GBM. We further revealed that sterol O-acyltransferase 1 (SOAT1), the key enzyme controlling cholesterol esterification and LD formation, is highly expressed and correlated with LD prevalence in tumor tissues from GBM patients. Genetic or pharmacologic inhibition SOAT1 using avasimibe, a phase III clinical trial drug in human atherosclerosis patients, significantly suppressed GBM growth and prolongs survival in xenograft models. Moreover, we found that inhibition of SOAT1 suppressed sterol regulatory element-binding protein-1 (SREBP-1), a key transcription factor playing a central role in lipid synthesis, which underlies the molecular mechanism of targeting SOAT1-mediated GBM growth suppression. In summary, our data demonstrate that LDs/cholesterol esters uniquely formed in tumor tissues provides an ideal target to specifically inhibit GBM cells whereas sparing normal brain tissues, and reveal that blocking cholesterol storage via targeting SOAT1 represents a promising strategy for GBM treatment.
The correlation between tumor regression grade and retrieved lymph nodes status in locally advanced rectal cancer after neoadjuvant treatment: results from a prospective study
Authors: J. Zhang, Y. Deng, Y. Cai, H. Hu, J. Ling, J. Xiao, P. Lan, L. Wang, M. Huang, L. Kang, X. Wu, J. Wang
Journal: Annals of Oncology (2016)
Retrospective analysis of patients affected by diffuse large B cell lymphomas AIDS-related
Authors: M.M. Latocca, D. Dalu, C. Fasola, V. Filipazzi, S. Ferrario, N. Tosca, F. Brioschi, A. Bandera, L. Verga, D. De Francesco, E. Piazza
Journal: Annals of Oncology (2016)
health economics The effect of financial difficulties on clinical outcomes in Italian cancer patients: A pooled analysis of 16 academic prospective clinical trials
Authors: F. Perrone, C. Jommi, M. Di Maio, A. Gimigliano, C. Gridelli, S. Pignata, F. Ciardiello, F. Nuzzo, A. de Matteis, L. Del Mastro, J. Bryce, G. Daniele, A. Morabito, M.C. Piccirillo, G. Rocco, L. Guizzaro, C. Gallo
Journal: Annals of Oncology (2016)
Keratin mutations in patients with epidermolysis bullosa simplex: correlations between phenotype severity and disturbance of intermediate filament molecular structure
Authors: B. Jeřábková, J. Marek, H. Bučková, L. Kopečková, K. Veselý, J. Valíčková, J. Fajkus, L. Fajkusová
Journal: British Journal of Dermatology (2010)

Epidermolysis bullosa simplex (EBS) is an inherited skin
disorder caused by mutations in the keratin 5 (KRT5) and
keratin 14 (KRT14) genes, with fragility of basaů keratinocytes
leading to epidermal cytolysis and blistering. Mutations were
characterized using polymerase chain reaction (PCR) and DNA
sequencing. Further, to explore possible correlations with
function, the structural effects of the mutations in segment 2B
of KRT5 and KRT14 and associated with EBS in our patients. We
have identified mutations in the KRT5 and KRT14 genesin 16 of
23 families affected by EBS in the Czech republic. Eleven
different sequence variants were found, of which four have not
been reported previously.
TAS-102 in patients with metastatic colorectal cancer refractory to standard therapies including regorafenib
Authors: Yosuke Kito, Satoshi Hamauchi, Kentaro Yamazaki, Azusa Komori, Toshiki Masuishi, Hiroya Taniguchi, Keita Mori, Kei Muro, Hirofumi Yasui
Journal: Annals of Oncology (2016)
QLIF-06. SEXUAL FUNCTION IN PATIENTS WITH PRIMARY BRAIN TUMORS (PBTs)
Authors: Jacqueline Stone, Lisa DeAngelis
Journal: Neuro-Oncology (2016)

To determine if sexual function, defined by sexual drive, arousal, performance, and satisfaction, is compromised by PBTs and associated treatment. PBT patients are at risk of sexual dysfunction given direct effects on the hypothalamic-pituitary-gonadal axis, physical limitations, as well as high rates of comorbid depression and fatigue. Few data exist on this subject. One published study of 32 diffuse low-grade glioma patients undergoing surgical resection demonstrated that 53% of patients experienced a postoperative sexual change (Surbeck et al, 2015). This is an IRB-approved cross-sectional analysis of adults with PBTs who were approached to complete a voluntary, anonymous survey, based on the Arizona Sexual Experience Scale, to evaluate the impact of their PBT and treatment on sexual function. Implications for quality of life were assessed. 56 PBT patients were approached, 31 completed the survey (55%). The study included 17 men and 14 women, median age 49. There were 6 patients with low grade tumors and 25 with high grade tumors. Two patients reported pre-existing sexual dysfunction. All patients had received treatment: 27 underwent surgical resection, 26 received radiotherapy, and 28 received chemotherapy. As compared to their sexual function prior to PBT diagnosis, 55% of patients reported a decrease in sex drive, 35% reported more difficulty becoming aroused, 42% reported more difficulty achieving orgasm, and 39% reported less sexual satisfaction. Ten patients (32%) noted that sexual function plays an important role in their quality of life (QOL). Sixty-eight percent conveyed that they would not want to discuss sexual function with their clinical team, but the remaining patients noted that they were unsure or would welcome the opportunity to discuss such issues. Sexual function is likely compromised in PBT patients and this reduces QOL. This study is on-going and the full results will be reported at the meeting.
TMOD-32. MATHEMATICALLY MODELING PERINEURAL SPREAD ALONG PERIPHERAL NERVES
Authors: Joshua Jacobs, Stepan Capek, Robert Spinner, Kristin Swanson
Journal: Neuro-Oncology (2016)

The perineural spread of cancers to and along the peripheral nerve system is an emerging explanation for neoplastic plexopathy and underestimated source of patient morbidity and mortality. The perineural spread is a slowly growing process and can be difficult to detect without diligence for those at risk. This can lead to significant loss of mobility, function, and reduced quality of life for patients affected. Building on previous results in modeling glioblastoma multiforme, we present a mathematical model for predicting the course and extent of the perineural spread of recurrent tumors. By tracking cancer growth in the lumbosacral plexus on contrast enhancing images of two patients (one with prostate cancer, one with cervical cancer) we calibrate a model for growth in a digitized atlas. We successfully modeled and simulated perineural growth in both patients. Although in early stages of development, our model shows promise in predicting the course and extent of perineural spread for many types of recurrent cancers. Furthermore, it may be used to evaluate the effectiveness of treatment in deflecting the growth of disease and maintaining function. Coupled with molecular profiles from multiple primary cancers, mathematical modeling may be a powerful tool in preventing or treating their perineural spread.